| Literature DB >> 30175086 |
Joseph E Dib1, Clive E Adams2, Francois Kazour3,4,5,6, Fouad Tahan3, Georges Haddad3,5, Chadia Haddad3, Souheil Hallit3,7.
Abstract
Background: Violent patients constitute 10% of all psychiatric admissions. Treatment options and clinical practice interventions vary across the globe and no survey of practice in a Middle Eastern setting exists. Surveying treatments in Lebanon will show treatment interventions used in this part of the world and, most importantly, provide the treatment options that could potentially be used for clinical trials pertaining to emergency psychiatry.Entities:
Keywords: Aggression; Agitation; Lebanon; Pharmacotherapy; Psychiatric hospital; Survey
Year: 2018 PMID: 30175086 PMCID: PMC6113581 DOI: 10.14196/mjiri.32.60
Source DB: PubMed Journal: Med J Islam Repub Iran ISSN: 1016-1430
Reviews of clinical trials on agitation and interventions
| Completed and maintained reviews | |
| 'As required' medication regimens for seriously mentally ill people in hospital |
( |
| Benzodiazepines for psychosis-induced aggression or agitation |
( |
| Chlorpromazine for psychosis-induced aggression or agitation |
( |
| Clotiapine for acute psychotic illnesses |
( |
| Containment strategies for people with serious mental illness |
( |
| De-escalation techniques for psychosis-induced aggression |
( |
| Droperidol for acute psychosis |
( |
| Haloperidol for long-term aggression in psychosis |
( |
| Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation) |
( |
| Haloperidol plus promethazine for psychosis-induced aggression |
( |
| Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses |
( |
| Seclusion and restraint for serious mental illnesses |
( |
| Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses |
( |
| Reviews in the process of being completed | |
| Risperidone for psychosis-induced aggression or agitation |
( |
| Loxapine inhaler for psychosis-induced aggression |
( |
| Clozapine for people with schizophrenia and recurrent physical aggression |
( |
| Quetiapine for psychosis-induced aggression or agitation |
( |
Data results of Clinicians' Opinions
| Psychiatrist | Experience (years) | Frequency of treating emergencies | Intervention | ||||||
| #1 | #2 | #3 | #4 | #5 | #6 | #7 | |||
| 1 | 19 | Daily |
* |
** |
*** |
*** |
**** | ***, **** Physical Restraint, Chemical Restraint | *** Zuclopenthixol |
| 2 | 7 | Weekly |
** | **** Seclusion Room |
**** | ||||
| 3 | 13 | Daily |
* | * Therapeutic Intervention |
* |
* |
*** | ||
| 4 | 10 | Weekly |
** |
* |
*** | ||||
| 5 | 30 | Monthly |
* | *** Olanzapine (oral form) | |||||
HPL: Haloperidol + Promethazine + Chlorpromazine, IM: Intramuscular Injection, Codes: * Non-physical, ** Oral Medication, *** IM Medication, **** Restrictive
Background of episode
| Sex | Male | Female | Total | ||
| 25 (64%) | 14 (36%) | 39 (100%) | |||
| Age | Mode | Mean | Range | ||
| 31 (n=6) | 33 (SD 8.9) | 18-58 | |||
| Presentation | Families | Authorities | By themselves | Other | Total |
| 26 (67%) | 3 (8%) | 4 (10%) | 6 (15%) | 39 (100%) | |
| Before admission | |||||
| Restraints | Yes | No | Total | ||
| 7 (18%) | 32 (82%) | 39 (100%) | |||
| Medication | Yes | No | Total | ||
| 4 (10%) | 35 (90%) | 39 (100%) |
Episode data
| Ward | Male only | 18 (46%) |
| Male & Female | 12 (31%) | |
| Female only | 9 (23%) | |
| Total | 39 (100%) | |
| Day | Sunday | 1 (3%) |
| Monday | 12 (30%) | |
| Tuesday | 9 (23%) | |
| Wednesday | 6 (16%) | |
| Thursday | 7 (18%) | |
| Friday | 2 (5%) | |
| Saturday | 2 (5%) | |
| Total | 39 (100%) | |
| Frequency | Range | 1-12/day |
| Diagnosis | Schizophrenia | 10 (35%) |
| Bipolar Disorder | 12 (43%) | |
| Substance use | 3 (10%) | |
| Schizoaffective Disorder | 1 (4%) | |
| Brief Psychotic Disorder | 1 (4%) | |
| Delusional Disorder | 1 (4%) | |
| Total | 28 (100%) |
Intervention order
| First | Second | Third | Fourth | Fifth | Sixth | ||
| Non-drug interventions | Verbal Command | 1 | |||||
| Strait jacket | 6 | 2 | 1 | ||||
| Drug interventions (all IM) | Diazepam | 8 | 5 | 2 | 1 | ||
| Haloperidol + Promethazine + Chlorpromazine | 7 | 5 | 4 | 1 | 1 | ||
| Haloperidol + Promethazine +/- Benzhexol | 4 | 4 | |||||
| Chlorpromazine + Lorazepam | 2 | ||||||
| Lorazepam | 2 | 2 | 1 | ||||
| Zuclopenthixol + Promethazine | 2 | 1 | |||||
| Chlorpromazine | 1 | 3 | 3 | 2 | 1 | ||
| Chlorpromazine + Promethazine | 1 | ||||||
| Diazepam + Lorazepam + Promethazine | 1 | ||||||
| Haloperidol | 1 | ||||||
| Haloperidol + Promethazine + Chlorpromazine + Lorazepam | 1 | ||||||
| Olanzapine | 1 | ||||||
| Zuclopenthixol | 1 | 1 | |||||
| Promethazine | 4 | 1 | 4 | 2 | 1 | ||
| Clozapine | 1 | ||||||
| Benzhexol | 3 | ||||||
| Total | 39 | 25 | 14 | 8 | 7 | 1 |
Recommendations for first line treatment of aggression thought due to serious mental illness
| Medication(s) | |||||||||
| Country | 1st author | Year | Cite | Verbal | Antipsychotic | Benzodiazepine | Combination | Physical | |
| Clinician Opinion | African Countries - multiple | Bawo | 2011 |
( | Diazepam | ||||
| Belgium | Bervoets | 2015 |
( | Olanzapine | |||||
| United Kingdom | Cunnane | 1994 |
( | Chlorpromazine | |||||
| Thacker | 1996 |
( | Haloperidol | ||||||
| Simpson | 1996 |
( | Haloperidol | ||||||
| Reid | 2003 |
( | Droperidol | ||||||
| Pereira | 2006 |
( | Lorazepam | ||||||
| U.S.A. | Binder | 1998 |
( | Restraint | |||||
| Australasia | Chan | 2011 |
( | Midazolam | |||||
| U.S.A | Allen | 2004 |
( | Restraint | |||||
| Australia | Cannon | 2001 |
( | Haloperidol | |||||
| Surveys of Practice | Brazil | Huff | 2002 |
( | Haloperidol + Promethazine | ||||
| Canada | Rapp | 1986 |
( | Haloperidol | |||||
| France | Moritz | 1999 |
( | Restraint | |||||
| Ireland | Mannion | 1997 |
( | Zuclopenthixol | |||||
| Multi national | Lepping | 2003 |
( | Haloperidol | Lorazepam | ||||
| United Kingdom | Cooper | 1983 |
( | Chlorpromazine | |||||
| Pilowski | 1992 |
( | Haloperidol | ||||||
| Haw | 2012 |
( | Diazepam | ||||||
| POMH | 2017 |
( | Lorazepam |